Tags

Type your tag names separated by a space and hit enter

Safety of neuraminidase inhibitors for influenza.
Expert Opin Drug Saf. 2006 Sep; 5(5):603-8.EO

Abstract

Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.

Authors+Show Affiliations

University of Queensland, Princess Alexandra Hospital, School of Population Health, Woolloongabba, Queensland 4102, Australia. m.jones@sph.uq.edu.auNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16907649

Citation

Jones, Mark, and Chis Del Mar. "Safety of Neuraminidase Inhibitors for Influenza." Expert Opinion On Drug Safety, vol. 5, no. 5, 2006, pp. 603-8.
Jones M, Del Mar C. Safety of neuraminidase inhibitors for influenza. Expert Opin Drug Saf. 2006;5(5):603-8.
Jones, M., & Del Mar, C. (2006). Safety of neuraminidase inhibitors for influenza. Expert Opinion On Drug Safety, 5(5), 603-8.
Jones M, Del Mar C. Safety of Neuraminidase Inhibitors for Influenza. Expert Opin Drug Saf. 2006;5(5):603-8. PubMed PMID: 16907649.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety of neuraminidase inhibitors for influenza. AU - Jones,Mark, AU - Del Mar,Chis, PY - 2006/8/16/pubmed PY - 2006/8/24/medline PY - 2006/8/16/entrez SP - 603 EP - 8 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 5 IS - 5 N2 - Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/16907649/Safety_of_neuraminidase_inhibitors_for_influenza_ L2 - http://www.tandfonline.com/doi/full/10.1517/14740338.5.5.603 DB - PRIME DP - Unbound Medicine ER -